LIPOSOMIAL IRON IS SAFE AND COST-EFFECTIVE IN HCV PATIENTS WITH TYPE II DIABETES AND ANEMIA DUE TO ESOPHAGEAL OR GASTRIC BLEEDING
(Abstract release date: 05/19/16)
EHA Library. GIORDANO G. 06/09/16; 135041; PB2141
Dr. GIULIO GIORDANO
Contributions
Contributions
Abstract
Abstract: PB2141
Type: Publication Only
Background
HCV patients frequently show anemia due to esophageal or gastric bleeding and type 2 diabetes. Iron support reduces degree of anemia. Iron support might cause hepatic function worsening or hepatocellular cancer onset. Non transferrin bound iron may sustain inflammation and increase insulin resistance.
Aims
Aim of this study is to verify if sucrosomial oral iron support vs ferric gluconate iv iron support vs transfusional support is safe and effective in patients with HCV treatment with iron deficiency anemia.
Methods
35 patients with HCV related anemia for esophageal varices and gastric bleeding with a median Hb level of 8 g/dl (R8-9.5 g/dl), were treated 15 with sucrosomial oral iron 30 mg 1 tablets t.i.d for 3 months (group A), 10 with i.v. ferric gluconate 62.5 mg/day for 15 days (group B) and 10 with 1 blood transfusion/day (group C) until Hb increase level of 1 g/dl was reached. Median Hb and glucose level in group A were 8 g/dl and 140 mg/dl respectively, in group B 9.5 g/dl and 130 mg/dl, in group C were 7 g/dl and 160 mg/dl. All patients received an abdomen echography to detect hepatocellular carcinoma (HCC) at 1, 3, 6 months.
Results
Patients in group A gained 1 g/dl Hb after 1 month (R 3-6 weeks), with a median blood glucose level of 130 mg/dl (R120-230) and a median cost of 30€/month (R 20-80), patients in group B gained 1 g/dl in 7 days (R 6-13 days), with a median blood glucose level of 310 mg/dl (R190-430) and a median cost of 1240€/month (R 830-2800), patients in group C gained 1 g/dl in 1 day (R 2-4 days), with a median blood glucose level of 210 mg/dl (R160-330) and a median cost of 400€/month (R 350-950). Only 1 patient in group B and 1 patient in group C developed HCC at 6 months. Worsening of liver function blood test was observed only in group C.
Conclusion
Liposomial iron is safe and cost-effective in HCV patients with type II diabetes and anemia due to esophageal or gastric bleeding
Session topic: E-poster
Keyword(s): Hepatitis C virus, Iron deficiency anemia
Type: Publication Only
Background
HCV patients frequently show anemia due to esophageal or gastric bleeding and type 2 diabetes. Iron support reduces degree of anemia. Iron support might cause hepatic function worsening or hepatocellular cancer onset. Non transferrin bound iron may sustain inflammation and increase insulin resistance.
Aims
Aim of this study is to verify if sucrosomial oral iron support vs ferric gluconate iv iron support vs transfusional support is safe and effective in patients with HCV treatment with iron deficiency anemia.
Methods
35 patients with HCV related anemia for esophageal varices and gastric bleeding with a median Hb level of 8 g/dl (R8-9.5 g/dl), were treated 15 with sucrosomial oral iron 30 mg 1 tablets t.i.d for 3 months (group A), 10 with i.v. ferric gluconate 62.5 mg/day for 15 days (group B) and 10 with 1 blood transfusion/day (group C) until Hb increase level of 1 g/dl was reached. Median Hb and glucose level in group A were 8 g/dl and 140 mg/dl respectively, in group B 9.5 g/dl and 130 mg/dl, in group C were 7 g/dl and 160 mg/dl. All patients received an abdomen echography to detect hepatocellular carcinoma (HCC) at 1, 3, 6 months.
Results
Patients in group A gained 1 g/dl Hb after 1 month (R 3-6 weeks), with a median blood glucose level of 130 mg/dl (R120-230) and a median cost of 30€/month (R 20-80), patients in group B gained 1 g/dl in 7 days (R 6-13 days), with a median blood glucose level of 310 mg/dl (R190-430) and a median cost of 1240€/month (R 830-2800), patients in group C gained 1 g/dl in 1 day (R 2-4 days), with a median blood glucose level of 210 mg/dl (R160-330) and a median cost of 400€/month (R 350-950). Only 1 patient in group B and 1 patient in group C developed HCC at 6 months. Worsening of liver function blood test was observed only in group C.
Conclusion
Liposomial iron is safe and cost-effective in HCV patients with type II diabetes and anemia due to esophageal or gastric bleeding
Session topic: E-poster
Keyword(s): Hepatitis C virus, Iron deficiency anemia
Abstract: PB2141
Type: Publication Only
Background
HCV patients frequently show anemia due to esophageal or gastric bleeding and type 2 diabetes. Iron support reduces degree of anemia. Iron support might cause hepatic function worsening or hepatocellular cancer onset. Non transferrin bound iron may sustain inflammation and increase insulin resistance.
Aims
Aim of this study is to verify if sucrosomial oral iron support vs ferric gluconate iv iron support vs transfusional support is safe and effective in patients with HCV treatment with iron deficiency anemia.
Methods
35 patients with HCV related anemia for esophageal varices and gastric bleeding with a median Hb level of 8 g/dl (R8-9.5 g/dl), were treated 15 with sucrosomial oral iron 30 mg 1 tablets t.i.d for 3 months (group A), 10 with i.v. ferric gluconate 62.5 mg/day for 15 days (group B) and 10 with 1 blood transfusion/day (group C) until Hb increase level of 1 g/dl was reached. Median Hb and glucose level in group A were 8 g/dl and 140 mg/dl respectively, in group B 9.5 g/dl and 130 mg/dl, in group C were 7 g/dl and 160 mg/dl. All patients received an abdomen echography to detect hepatocellular carcinoma (HCC) at 1, 3, 6 months.
Results
Patients in group A gained 1 g/dl Hb after 1 month (R 3-6 weeks), with a median blood glucose level of 130 mg/dl (R120-230) and a median cost of 30€/month (R 20-80), patients in group B gained 1 g/dl in 7 days (R 6-13 days), with a median blood glucose level of 310 mg/dl (R190-430) and a median cost of 1240€/month (R 830-2800), patients in group C gained 1 g/dl in 1 day (R 2-4 days), with a median blood glucose level of 210 mg/dl (R160-330) and a median cost of 400€/month (R 350-950). Only 1 patient in group B and 1 patient in group C developed HCC at 6 months. Worsening of liver function blood test was observed only in group C.
Conclusion
Liposomial iron is safe and cost-effective in HCV patients with type II diabetes and anemia due to esophageal or gastric bleeding
Session topic: E-poster
Keyword(s): Hepatitis C virus, Iron deficiency anemia
Type: Publication Only
Background
HCV patients frequently show anemia due to esophageal or gastric bleeding and type 2 diabetes. Iron support reduces degree of anemia. Iron support might cause hepatic function worsening or hepatocellular cancer onset. Non transferrin bound iron may sustain inflammation and increase insulin resistance.
Aims
Aim of this study is to verify if sucrosomial oral iron support vs ferric gluconate iv iron support vs transfusional support is safe and effective in patients with HCV treatment with iron deficiency anemia.
Methods
35 patients with HCV related anemia for esophageal varices and gastric bleeding with a median Hb level of 8 g/dl (R8-9.5 g/dl), were treated 15 with sucrosomial oral iron 30 mg 1 tablets t.i.d for 3 months (group A), 10 with i.v. ferric gluconate 62.5 mg/day for 15 days (group B) and 10 with 1 blood transfusion/day (group C) until Hb increase level of 1 g/dl was reached. Median Hb and glucose level in group A were 8 g/dl and 140 mg/dl respectively, in group B 9.5 g/dl and 130 mg/dl, in group C were 7 g/dl and 160 mg/dl. All patients received an abdomen echography to detect hepatocellular carcinoma (HCC) at 1, 3, 6 months.
Results
Patients in group A gained 1 g/dl Hb after 1 month (R 3-6 weeks), with a median blood glucose level of 130 mg/dl (R120-230) and a median cost of 30€/month (R 20-80), patients in group B gained 1 g/dl in 7 days (R 6-13 days), with a median blood glucose level of 310 mg/dl (R190-430) and a median cost of 1240€/month (R 830-2800), patients in group C gained 1 g/dl in 1 day (R 2-4 days), with a median blood glucose level of 210 mg/dl (R160-330) and a median cost of 400€/month (R 350-950). Only 1 patient in group B and 1 patient in group C developed HCC at 6 months. Worsening of liver function blood test was observed only in group C.
Conclusion
Liposomial iron is safe and cost-effective in HCV patients with type II diabetes and anemia due to esophageal or gastric bleeding
Session topic: E-poster
Keyword(s): Hepatitis C virus, Iron deficiency anemia
{{ help_message }}
{{filter}}